ArticleFood science & nutrition2025
The Effect of Boron Supplementation on Kidney Stones in Patients With Nephrolithiasis: A Double-Blind Randomized Controlled Trial.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Boron Supplementation on Kidney Stones in Patients With Nephrolithiasis: A Double-Blind Randomized Controlled Trial.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney stones (nephrolithiasis) are a common and costly medical condition frequently linked with metabolic disorders. These disorders elevate the risk of serious complications and often necessitate invasive, expensive treatments, highlighting the need for alternative therapies. This study aimed to evaluate the effects of boron supplementation-in the form of boric acid and boron citrate-on kidney stone size and number in patients with nephrolithiasis. In this double-blind, randomized, placebo-controlled clinical trial, 60 eligible patients aged 20-65 years with nephrolithiasis were enrolled. Participants were randomly assigned to receive daily oral supplements for 8 weeks: boric acid (10 mg), boron citrate (10 mg), or placebo. The primary outcomes were kidney stone size and number; secondary outcomes included paraclinical parameters. Boron supplementation with either boric acid or boron citrate did not significantly reduce the number of kidney stones in fully adjusted models compared to the control group. The incidence rate ratios (IRR) were 1.09 (95% CI: 0.65-1.85;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.